Health Care • Biotechnology: Pharmaceutical Preparations
$0.51 ▲ +0.02
(+3.88%)
MKT CAP: $9.4M • VOL: 157.3K
52W L $0 52W H $2
ROARABLE / RQD
D- • 40/100
PIOTROSKI
3 / 9
BFRG // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $116.7K | $0 | $65.0K |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | $21.9K | — | — |
| Gross Margin % | 18.8% | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$6.6M | -$7.2M | -$5.4M |
| Operating Margin % | -80.0% | — | -80.0% |
| Net Income (GAAP) | -$6.5M | -$7.0M | -$5.4M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$5.5M | -$5.6M | -$6.0M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$5.5M | -$5.6M | -$6.0M |
| FCF Margin % | -80.0% | — | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $2.2M | $5.4M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $2.1M | $5.0M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR BFRG.